In a certain way, life with pulmonary hypertension (PH) can resemble a social media profile. What other people see may appear polished, remain private and guarded, or be raw and heavy — but it rarely reveals the whole story. A social media profile is not necessarily false simply because…
Discussion
People with severe pulmonary arterial hypertension (PAH) who respond well to early treatment with prostacyclin infusions may be able to reduce or stop the treatment, a study suggested. In a long-term analysis of 101 patients, about one in five achieved enough improvement in heart and lung blood flow measurements…
Discussion
In China, Volibris (ambrisentan, sold as Letairis and generics in the U.S.) may have advantages over similar medications for pulmonary arterial hypertension (PAH) when considering factors including safety, efficacy, and economic value. That’s according to a study in which a team of experts developed a multi-criteria decision analysis…
Discussion
Restoring the levels of BMP3, a naturally occurring protein involved in cell communication that regulates pulmonary blood vessels, reversed key features of pulmonary arterial hypertension (PAH) in preclinical models, a study found. Compared with people without PAH, levels of BMP3 were lower in lung tissue, smooth muscle cells that…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
